Danaher, Innovative Genomics Institute partner on CRISPR-based therapies
The Danaher-IGI Beacon for CRISPR Cures centre will use CRISPR-based gene editing technology to drive pre-clinical gene-editing therapies…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
10 Jan 24
The Danaher-IGI Beacon for CRISPR Cures centre will use CRISPR-based gene editing technology to drive pre-clinical gene-editing therapies…
10 Jan 24
AbbVie has launched the solution to treat PD with severe motor fluctuations and hyperkinesia or dyskinesia, and when…
10 Jan 24
Under the agreement, Menarini will buy the exclusive rights to commercialise cefepime-taniborbactam in 96 countries in return for…
10 Jan 24
AR-15512, a topical transient receptor potential melastatin 8 (TRPM8) agonist, is a first-in-class product candidate for the treatment…
10 Jan 24
Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy
09 Jan 24
Through the acquisition, Johnson & Johnson will benefit from Ambrx’s portfolio of clinical and preclinical programmes, including lead…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
09 Jan 24
The collaboration is aimed at deepening comprehension of cell morphology, ultimately hastening the integration of AI-driven cellular analysis…
09 Jan 24
The acquisition will grant Merck access to Harpoon’s two immunotherapies in early-stage development, one for a type of…
09 Jan 24
The deal is expected to grant Novartis access to Cytokinetics' experimental treatment for hypertrophic cardiomyopathy treatment, Aficamten, which…
09 Jan 24
EU health regulator has approved the combination for adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom…